These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34251864)

  • 21. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.
    Zhang L; Vickers TA; Sun H; Liang XH; Crooke ST
    Nucleic Acids Res; 2021 Mar; 49(5):2721-2739. PubMed ID: 33577678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Directed RNase H Cleavage of Nascent Transcripts Causes Transcription Termination.
    Lai F; Damle SS; Ling KK; Rigo F
    Mol Cell; 2020 Mar; 77(5):1032-1043.e4. PubMed ID: 31924447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway.
    Liang XH; Nichols JG; Hsu CW; Vickers TA; Crooke ST
    Nucleic Acids Res; 2019 Jul; 47(13):6900-6916. PubMed ID: 31165876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
    Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
    Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides.
    Løvendorf MB; Holm A; Petri A; Thrue CA; Uchida S; Venø MT; Kauppinen S
    Nucleic Acid Ther; 2023 Jan; 33(1):45-57. PubMed ID: 36445751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Golgi-58K can re-localize to late endosomes upon cellular uptake of PS-ASOs and facilitates endosomal release of ASOs.
    Liang XH; Nichols JG; De Hoyos CL; Sun H; Zhang L; Crooke ST
    Nucleic Acids Res; 2021 Aug; 49(14):8277-8293. PubMed ID: 34244781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.
    Vickers TA; Crooke ST
    Nucleic Acids Res; 2015 Oct; 43(18):8955-63. PubMed ID: 26384424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.
    Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
    Nucleic Acids Res; 2016 Sep; 44(15):7314-30. PubMed ID: 27378781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.
    Lok CN; Viazovkina E; Min KL; Nagy E; Wilds CJ; Damha MJ; Parniak MA
    Biochemistry; 2002 Mar; 41(10):3457-67. PubMed ID: 11876654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
    Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
    Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
    Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
    Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines.
    Michel S; Schirduan K; Shen Y; Klar R; Tost J; Jaschinski F
    Mol Diagn Ther; 2021 Jan; 25(1):77-85. PubMed ID: 33314011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity.
    Liang XH; Nichols JG; De Hoyos CL; Crooke ST
    Nucleic Acids Res; 2020 Sep; 48(17):9840-9858. PubMed ID: 32870273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.